Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

Leukemia. 2020 Nov;34(11):3091-3096. doi: 10.1038/s41375-020-0750-z. Epub 2020 Mar 11.

on behalf of NCRI Haematology Clinical Studies Group:
Peter Hillman, Lesley Anderson, Stephen O'Brien, Jim Cavet, Oliver Ottman, Alan Chant, Alasdair Rankin, Gordon Cook, Clare Rowntree, Charles Craddock, Anna Schuh, Lavinia Davey, Shamyla Siddique, Walter Gregory, Simon Stanworth, Sally Killick, Simon Watt, Amy Kirkwood, Kwee Yong, Dragana Milojkovic, Thomas Fox, Adam Mead, Gillian Horne, Gillian Murphy, Kikkeri Naresh

¹ Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
² Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
³ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
⁴ Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
⁵ Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
⁶ Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
⁷ Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
⁸ Molecular and Population Genetics, The Institute of Cancer Research, London, UK.
⁹ Department of Haematology, University of Newcastle, Newcastle Upon Tyne, UK.
¹⁰ Division of Molecular Pathology, The Institute of Cancer Research, London, UK. Martin.Kaiser@icr.ac.uk.

^# Contributed equally.

No abstract available

Publication types